ApoB and Lp(a): the two cardiovascular numbers your standard German check-up does not measure

Your standard cholesterol panel reports LDL-C. That is just the weight of the cholesterol packed inside LDL particles. ApoB does something different. It counts the particles themselves. Every atherogenic lipoprotein (the bad-actor fat-carriers: LDL, VLDL, IDL, Lp(a), chylomicron remnants) carries exactly one molecule of apolipoprotein B. So ApoB tells you how many particles can actually slip into your arterial wall and start a plaque.

For most people, LDL-C and ApoB tell the same story. The trouble starts in the people who matter most for prevention: those with type 2 diabetes, metabolic syndrome, belly fat (central adiposity), or high triglycerides. Their LDL particles tend to be small and cholesterol-poor. So they carry a lot of particles for a given LDL-C mass. Allan Sniderman has spent two decades documenting this mismatch, which he calls "discordance" (his 2019 narrative review in JAMA Cardiology). For these people, LDL-C quietly underestimates the risk. ApoB tracks it.

That is why the 2019 ESC/EAS dyslipidaemia guidelines bumped ApoB up to a Class I recommendation for risk assessment when triglycerides are high, or in diabetes, obesity, metabolic syndrome, or very low LDL-C. The 2025 ESC/EAS focused update doubled down: ApoB is the preferred marker in those settings. The US ACC/AHA 2018 cholesterol guideline is more conservative, but it still accepts ApoB and non-HDL-C as valid alternatives.

One honest caveat about how strong the evidence is. The case for ApoB beating LDL-C rests on big observational studies (UK Biobank, Copenhagen General Population Study) and Mendelian randomization analyses (a genetics method that mimics a trial). We do not yet have a randomized trial that pits "treat to ApoB" against "treat to LDL-C" for hard cardiovascular endpoints. The mechanistic and epidemiological case is strong. It is just not RCT-grade. So read those "ApoB superiority" headlines with that footnote in mind.

Lipoprotein(a) is an LDL-like particle with one extra protein, apolipoprotein(a), bolted on. Your blood level is set 70 to 90% by your LPA gene. It locks in by your mid-twenties. Diet, exercise, statins, and almost every lifestyle lever barely move it. Roughly one in five people of European ancestry carries levels linked to higher atherosclerotic and aortic-valve risk. The prevalence is even higher in people of African ancestry.

The science here is solid. A 2009 JAMA meta-analysis from the Emerging Risk Factors Collaboration pooled 36 prospective studies and nailed down the independent, continuous link between Lp(a) and coronary heart disease. A 2017 "Test in Context" review in JACC then cemented Lp(a) as a causal, independent risk factor. And the EAS 2022 Consensus Statement (the Kronenberg paper, European Heart Journal) landed the modern view: every adult should have Lp(a) measured at least once in their lifetime, as part of a full cardiovascular risk assessment.

Now the expectation-management part. As of 2026, no drug is approved specifically to lower Lp(a). Three large outcome trials are running. Lp(a) HORIZON tests pelacarsen, an antisense oligonucleotide (a gene-silencing drug), from Ionis/Novartis. OCEAN(a)-Outcomes tests olpasiran, an siRNA, from Amgen. ACCLAIM-Lp(a) tests lepodisiran, an siRNA, from Eli Lilly. None has reported primary cardiovascular endpoints yet. None is approved by the EMA or the FDA. PCSK9 inhibitors do nudge Lp(a) down (roughly 25 to 30% in FOURIER and ODYSSEY OUTCOMES; a pooled meta-analysis in JACC Advances, 2025, put it at -27%, 95% CI -29.8% to -24.1%) as a side effect of lowering LDL-C. They are not licensed for Lp(a) itself.

So what actually changes when you find out your Lp(a) is high? The rest of your risk picture. Guidelines and clinical practice agree on this: hit every modifiable risk factor harder (blood pressure, ApoB-containing lipoproteins, smoking, blood glucose) to offset the Lp(a) burden you cannot change. That recalibration is the real, practical value of the test.

Lab reports use different units and reference ranges. That alone causes half the confusion. ApoB shows up in g/L or mg/dL. Lp(a) shows up either in mass units (mg/dL) or, the ESC/EAS preference, in molar units (nmol/L). The two are not interchangeable, because Lp(a) isoforms vary in size. Always check which unit your report uses before you compare yourself to a number you read online.

For ApoB, the 2019 ESC/EAS guideline sets goals by your overall cardiovascular risk category, not by one single threshold. People at very high risk are expected to reach a much lower ApoB than people at low risk. Same logic as LDL-C. The 2025 focused update kept this risk-stratified approach. A single number on a screen, cut off from your age, blood pressure, smoking status, family history, and other risk factors, cannot tell you what your target should be. That is a conversation for your Kardiologin or Hausärztin.

For Lp(a), the EAS 2022 consensus calls the risk continuous. There is no clean cut-off where danger suddenly starts. Many labs flag values above roughly 50 mg/dL or 105 to 125 nmol/L as elevated (isoform-correction varies between methods; the 2025 ESC/EAS Focused Update on dyslipidaemia uses 105 nmol/L specifically). The EAS document itself calls the relationship graded. Very high values (say, above 180 mg/dL or 430 nmol/L) roughly double your lifetime cardiovascular risk compared with the general population. That is similar in size to heterozygous familial hypercholesterolaemia, an inherited high-cholesterol condition. Your number is one input among many.

Two practical things to keep in mind. First, read both markers alongside a full lipid panel, hs-CRP (an inflammation marker), blood pressure, glucose or HbA1c, and an honest family history. Second, primary prevention (you have never had an event) and secondary prevention (you have) follow different treatment logics. The same Lp(a) value means different things in those two contexts.

The German statutory Check-up 35 (Gesundheitsuntersuchung), which Kassenpatienten can claim every three years from age 35, covers a basic lipid panel: total cholesterol, HDL-C, LDL-C, triglycerides. ApoB and Lp(a) are not on the list. Neither is hs-CRP, fasting insulin, or HbA1c, outside specific clinical reasons. Your Hausärztin is doing exactly what the GKV check-up specifies. She just is not doing what a longevity-curious patient might want her to add on.

This is not a German quirk born of neglect. Most national primary-care systems anchor on LDL-C, because LDL-C is what most of the trial evidence and risk scores were built on. ApoB and Lp(a) only entered the guidelines as risk-refiners more recently. And primary-care reimbursement schedules trail the guidelines by years. The DGFF (Deutsche Gesellschaft zur Bekämpfung von Fettstoffwechselstörungen, also known as Lipid-Liga) pushes hard for broader Lp(a) testing, but coverage decisions sit with the G-BA, not the medical societies.

So for most patients the practical answer is simple. ApoB and Lp(a) are usually IGeL (Individuelle Gesundheitsleistung), meaning self-pay add-ons, unless you have a clear clinical indication. Indications that might shift them into Kassen-paid territory include known coronary artery disease, premature familial cardiovascular disease, statin intolerance, very high LDL-C that raises suspicion of familial hypercholesterolaemia, or recurrent events despite well-controlled LDL-C. Bring a documented family history. It is genuinely the single most useful thing you can hand a GP making this call.

If your Hausärztin declines to order them, that is normal. It is not an insult to her judgement. Your realistic options: ask her to add them as an IGeL/Selbstzahler line on your next lab draw, or use a Selbstzahler service that orders from a major lab like Synlab, Limbach, or Sonic on your behalf. Both routes use the same labs.

In Germany, ApoB and Lp(a) are routinely available through the three big laboratory networks: Synlab, Limbach, and Sonic Healthcare (Bioscientia, Medizinische Labore Volkmann, MVZ Augsburg, and others). Either your Hausärztin orders them and bills you privately under GOÄ (Gebührenordnung für Ärzte), or you use a Selbstzahler service that ships your blood to one of those same labs. As a rough orientation: Lp(a) tends to run about 20 to 40 EUR, ApoB about 10 to 25 EUR per marker as a Selbstzahler. Add venepuncture and a service fee on top. The exact number depends on the lab, the region, and whether the markers are part of a wider panel. Verify before you order. Online prices drift, and some are promotional.

In Austria, the Wahlarzt model is the usual route. A Wahlarzt or Wahlarzt-Labor draws your blood, bills you privately, and you submit the invoice to your Krankenkasse for partial reimbursement under standard rules. You typically get back around 80% of the equivalent Kassen tariff. For niche markers like Lp(a), that can be a lot less than you actually paid. ÖGK does not generally reimburse Lp(a) testing outside specific clinical indications.

In Switzerland the picture is the simplest in some ways and the most expensive in others. Without a clear medical indication, both ApoB and Lp(a) are almost always self-paid out of your annual Franchise plus the Selbstbehalt. Lab prices run higher than in Germany or Austria. A rough range for combined ApoB and Lp(a) is comparable to or above 100 CHF. The upside: you skip the IGeL conversation entirely. If your Hausarzt or Kardiologe sees an indication, the test goes through OKP and you carry the standard cost-sharing.

A few practical tips travel across all three countries. Fast for 10 to 12 hours if your panel includes triglycerides and your doctor agrees. ApoB and Lp(a) themselves are not strongly fasting-dependent, but the rest of the panel may be. Sit calmly for ten minutes before the draw. Avoid an acute illness or recent vaccination, which can briefly shift lipids and especially Lp(a). And ask the lab in advance which Lp(a) unit (mg/dL or nmol/L) and which assay (isoform-insensitive is preferred) they use.

First, and most important: this guide does not prescribe a protocol. If your ApoB or Lp(a) comes back elevated, your next step is a conversation. With your Hausärztin, or better, a Kardiologin or a lipidology-trained Wahlärztin/Wahlarzt. The decision tree branches heavily on your age, your other risk factors, your family history, and whether you are in primary or secondary prevention. There is no single right answer.

So what makes that conversation productive? Bring your full lipid panel, a documented family history of cardiovascular events (with ages), your blood pressure trend, glucose or HbA1c if you have it, your smoking status, and a list of medications. Ask explicit questions. Do not expect your doctor to volunteer them. Useful ones: "Where does my overall ESC SCORE2 risk land?" "Does my Lp(a) push me into a higher-risk band that changes how aggressively we treat my LDL-C and blood pressure?" "Is a coronary calcium score (CAC) reasonable for me as a tiebreaker?" "Are there indications for lipid-lowering therapy that I meet, given my full picture?"

On lifestyle, read this part carefully. The Mediterranean dietary pattern, regular aerobic and resistance exercise, not smoking, sleeping enough, and keeping belly fat (central adiposity) in check all improve cardiovascular outcomes and modestly improve ApoB-containing lipoproteins. They will not normalize a genetically high Lp(a). Treating lifestyle as "the Lp(a) protocol" is exactly the magical thinking this guide is trying to avoid. Lifestyle is worth doing on its own merits, whatever your Lp(a) is. Frame it that way.

One last word on the longevity-medicine framing that floats around social media. It is genuinely useful for some people to know their ApoB and Lp(a) earlier rather than later, especially those with a strong family history of premature cardiovascular events. It is not useful for an asymptomatic healthy person with no family history to spiral into anxiety over a single elevated number. Test if you can act on the result with a clinician you trust. Otherwise, the test is just information you cannot use.